What is she best known for?
The fields of study she is best known for:
- Cancer
- Gene
- Internal medicine
Suzanne Kamel-Reid mainly focuses on Internal medicine, Oncology, Cancer research, Cancer and Carcinoma.
Her work deals with themes such as Surgery and Immunology, which intersect with Internal medicine.
Her Oncology research is multidisciplinary, incorporating perspectives in Clinical trial and Epidermal growth factor receptor.
Her work on Imatinib mesylate as part of general Cancer research study is frequently linked to Hydroxymethylglutaryl-CoA reductase, bridging the gap between disciplines.
Her Erlotinib research incorporates elements of KRAS, Survival analysis and Hazard ratio.
Her research integrates issues of EGFR Gene Amplification and Adenocarcinoma in her study of Erlotinib Hydrochloride.
Her most cited work include:
- Erlotinib in lung cancer - molecular and clinical predictors of outcome. (1679 citations)
- Erlotinib in lung cancer - molecular and clinical predictors of outcome. (1679 citations)
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results (1004 citations)
What are the main themes of her work throughout her whole career to date?
Suzanne Kamel-Reid focuses on Internal medicine, Oncology, Cancer research, Pathology and Cancer.
Her work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Surgery.
The various areas that Suzanne Kamel-Reid examines in her Oncology study include Immunology, Bioinformatics and Hazard ratio.
She has included themes like Haematopoiesis, Stem cell and NPM1 in her Immunology study.
In her work, Retinoic acid receptor alpha and Molecular biology is strongly intertwined with Acute promyelocytic leukemia, which is a subfield of Cancer research.
Erlotinib is a subfield of Epidermal growth factor receptor that Suzanne Kamel-Reid studies.
She most often published in these fields:
- Internal medicine (52.58%)
- Oncology (42.72%)
- Cancer research (24.18%)
What were the highlights of her more recent work (between 2016-2021)?
- Internal medicine (52.58%)
- Oncology (42.72%)
- DNA sequencing (7.28%)
In recent papers she was focusing on the following fields of study:
Internal medicine, Oncology, DNA sequencing, KRAS and Lung cancer are her primary areas of study.
Her Oncology study combines topics in areas such as Cancer, Metastasis, Germline mutation and Hazard ratio.
Her studies in DNA sequencing integrate themes in fields like Bioinformatics, Myeloid, Standard of care, Genomic sequencing and Computational biology.
Her KRAS study incorporates themes from Serous fluid and Adenocarcinoma.
Her work in the fields of Lung cancer, such as Non small cell, intersects with other areas such as Context.
Her DNA profiling research is multidisciplinary, incorporating elements of Cancer research and Immunology.
Between 2016 and 2021, her most popular works were:
- Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. (243 citations)
- Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. (243 citations)
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). (72 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Her main research concerns Internal medicine, Oncology, DNA sequencing, KRAS and Pathology.
In the field of Internal medicine, her study on Radiation therapy, Clinical trial and Hazard ratio overlaps with subjects such as Laboratory Proficiency Testing and In patient.
Suzanne Kamel-Reid works in the field of Oncology, namely Lung cancer.
Her research in DNA sequencing intersects with topics in Molecular pathology, Computational biology, MEDLINE and Bioinformatics.
The concepts of her Pathology study are interwoven with issues in Polymerase chain reaction and In situ hybridization.
The study incorporates disciplines such as Liquid biopsy and Cancer research in addition to Immunology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
